Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine?

Autor(es)

da Silva, Lais Teodoro ^[1] ; Pontillo, Alessandra ^{[2, 1]} ; da Silva, Wanessa Cardoso ^[1] ; de Almeida, Alexandre ^[1] ; da Silva Duarte, Alberto Jose ^[1] ; Oshiro, Telma Miyuki ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Med, Dept Dermatol, Lab Med Invest Dermatol & Immunodeficiencies LIM, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Immunogenet Lab, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Immunotherapy; v. 5, n. 12, p. 1305-1311, DEC 2013.
• Citações Web of Science: 0

Resumo

Aims: HIV-1 expanded in an allogenic system (Al-HIV) represents a cheaper and faster alternative to the autologous virus (Au-HIV) as an antigen in anti-HIV immunotherapy. In this study, chemically inactivated HIV-1 obtained through autologous or allogenic systems were compared. Patients \& methods: Au-HIV and Al-HIV obtained from cultures of peripheral blood mononuclear cells from 11 HIV+ individuals were tested for virus production, yield and time of culture, and their ability to elicit a specific immune response in vitro. Results: The allogenic system was more efficient than the autologous system. Dendritic cells pulsed with Au-HIV and Al-HIV presented a similar phenotypic profile, but only Al-HIV induced a significant increase in IFN-(+) lymphocytes. Conclusion: The use of an allogenic system displays several advantages in terms of cell manipulation, time and cost of culture, and immunogenicity. (AU)

• Processo FAPESP: 12/18879-6 - Caracterização das células dendríticas utilizadas em um ensaio clínico de Fase I/II de vacina terapêutica anti-HIV
• Beneficiário: Telma Miyuki Oshiro Sumida
• Modalidade de apoio: Auxílio à Pesquisa - Regular